Adagio Therapeutics Shares Rise Premarket on ADG20 Omicron Update >ADGI

- Advertisement -


Colin Kellaher. By

- Advertisement -
- Advertisement -

Adagio Therapeutics Inc. Shares of U.S. stocks jumped more than 15% in premarket trading on Thursday after the clinical-stage biopharmaceutical company delivered a positive update on ADG20, its key monoclonal antibody in the fight against Covid-19.

The Waltham, Mass., company said findings reported in three separate publications show that ADG20 has neutralizing activity against the Omicron variant, which is responsible for the recent surge in COVID-19 cases around the world. .

- Advertisement -

Adagio, which is studying ADG20 in global Phase 2/3 trials for both prevention and treatment of Covid-19, also said it is in discussions with the US Food and Drug Administration about possible protocol updates to the study. including increased dosage. ADG20 for the prevention and treatment of Covid-19 caused by Omicron type.

Shares of Adagio, which closed Wednesday at $5.83, rose 17.3% to $6.84 in recent premarket trading.

Write to Colin Kellaher at [email protected]

,

- Advertisement -

Stay on top - Get the daily news in your inbox

DMCA / Correction Notice

Recent Articles

Related Stories

Stay on top - Get the daily news in your inbox